# Case Report: A successfully managed case of SMARCA4-deficient undifferentiated gastric carcinoma

## TL;DR

A rare stomach cancer case with SMARCA4 deficiency was successfully treated with a combination of therapies, leading to no recurrence after 33 months.

## Contribution

This is the first reported case of a successfully managed SMARCA4-deficient undifferentiated gastric carcinoma.

## Key findings

- The patient remained tumor-free for 33 months after treatment.
- Combination therapy with chemotherapy, immunotherapy, and targeted therapy showed promising results.
- The case challenges the typically poor prognosis of SMARCA4-deficient gastric tumors.

## Abstract

We report a case of SMARCA4-deficient poorly-to-undifferentiated gastric carcinoma. The patient underwent surgical resection. Postoperative treatment combined chemotherapy, immunotherapy, and targeted therapy. The regimen included ifosfamide, liposomal doxorubicin hydrochloride, cadonilimab, and anlotinib capsules. Follow-up to date shows no tumor recurrence or metastasis. The postoperative relapse-free survival (RFS) has now reached 33 months. Primary gastric SMARCA4-deficient undifferentiated tumors carry a poor prognosis, with survival typically under one year. Here we present a successfully treated case of this tumor type originating in the stomach. This case may serve as a reference for future management of such tumors.